Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Yahi

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Virology|December 24, 1997
Direct effect of type 1 human immunodeficiency virus (HIV-1) on intestinal epithelial cell differentiation: relationship to HIV-1 enteropathyO Delézay, N Yahi, C Tamalet, et al.
Nature|May 23, 1991
Discrepancies in AIDS virus dataJ C Chermann, G Donker, N Yahi, et al.
In Vitro Cellular & Developmental Biology. Animal|June 1, 1995
SPC3, a nontoxic peptide inhibitor of HIV infectionJ M Sabatier, S Baghdiguian, N Yahi, et al.
AIDS (London, England)|September 26, 1997
Co-expression of CXCR4/fusin and galactosylceramide in the human intestinal epithelial cell line HT-29O Delézay, N Koch, N Yahi, et al.
Comptes Rendus De L'Academie Des Sciences. Serie III, Sciences De La Vie|November 1, 1993
Multi-branched peptides based on the HIV-1 V3 loop consensus motif inhibit HIV-1 and HIV-2 infection in CD4+ and CD4- cellsJ Fantini, N Yahi, K Mabrouk, et al.
The Journal of Biological Chemistry|September 30, 1994
Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cellsN Yahi, J M Sabatier, P Nickel, et al.
Addiction Biology|June 26, 2010
Relationship between HIV-1 viral load and continued drug use in untreated infected injection drug usersM P Carrieri, C Tamalet, D Vlahov, et al.
AIDS (London, England)|August 1, 1994
Comparison of viral burden and phenotype of HIV-1 isolates from lymph nodes and bloodC Tamalet, A Lafeuillade, N Yahi, et al.
AIDS (London, England)|January 12, 2001
Evolution of HIV-1 multidrug-resistant genotypes during combination therapy and after the cessation of antiretroviral drugsN Yahi, C Tourrès, N Tivoli, et al.
European Annals of Otorhinolaryngology, Head and Neck Diseases|December 28, 2010
Degenerative pleomorphic adenoma of the nasal cavityY Yazibene, N Ait-Mesbah, S Kalafate, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Virology|December 24, 1997
Direct effect of type 1 human immunodeficiency virus (HIV-1) on intestinal epithelial cell differentiation: relationship to HIV-1 enteropathyO Delézay, N Yahi, C Tamalet, et al.
Nature|May 23, 1991
Discrepancies in AIDS virus dataJ C Chermann, G Donker, N Yahi, et al.
In Vitro Cellular & Developmental Biology. Animal|June 1, 1995
SPC3, a nontoxic peptide inhibitor of HIV infectionJ M Sabatier, S Baghdiguian, N Yahi, et al.
AIDS (London, England)|September 26, 1997
Co-expression of CXCR4/fusin and galactosylceramide in the human intestinal epithelial cell line HT-29O Delézay, N Koch, N Yahi, et al.
Comptes Rendus De L'Academie Des Sciences. Serie III, Sciences De La Vie|November 1, 1993
Multi-branched peptides based on the HIV-1 V3 loop consensus motif inhibit HIV-1 and HIV-2 infection in CD4+ and CD4- cellsJ Fantini, N Yahi, K Mabrouk, et al.
The Journal of Biological Chemistry|September 30, 1994
Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cellsN Yahi, J M Sabatier, P Nickel, et al.
Addiction Biology|June 26, 2010
Relationship between HIV-1 viral load and continued drug use in untreated infected injection drug usersM P Carrieri, C Tamalet, D Vlahov, et al.
AIDS (London, England)|August 1, 1994
Comparison of viral burden and phenotype of HIV-1 isolates from lymph nodes and bloodC Tamalet, A Lafeuillade, N Yahi, et al.
AIDS (London, England)|January 12, 2001
Evolution of HIV-1 multidrug-resistant genotypes during combination therapy and after the cessation of antiretroviral drugsN Yahi, C Tourrès, N Tivoli, et al.
European Annals of Otorhinolaryngology, Head and Neck Diseases|December 28, 2010
Degenerative pleomorphic adenoma of the nasal cavityY Yazibene, N Ait-Mesbah, S Kalafate, et al.
Pageof 6